Based on the identification of genes, such as RAS (a key signal transduction GTPase) and BRCA1 (a tumor suppressor involved in DNA damage repair) which show synthetic lethality with PLK1 inhibition (20, 49), the next generation PLK1 inhibitor onvansertib is currently being assessed in KRAS-mutated metastatic colorectal carcinoma patients in combination with FOLFIRI and bevacizumab, with promising overall response rates recently reported (50). The gene discussed is PLK1; the disease is neoplasm.